Trial Profile

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Zanidatamab (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Jazz Pharmaceuticals plc

Most Recent Events

29 May 2025 Planned End Date changed from 26 Oct 2025 to 30 Jun 2025.
08 Dec 2023 According to a Jazz Pharmaceuticals plc media release, data from this study were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
08 Dec 2023 Results presented in a Jazz Pharmaceuticals plc Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com